Agid O, Kapur S and Remington G (2008) Emerging drugs for schizophrenia. Expert opinion on emerging drugs 13:479-495.
Akhondzadeh S (1999) Hippocampal synaptic plasticity and cognition. Journal of clinical pharmacy and therapeutics 24:241-248.
Akkerman S, Blokland A and Prickaerts J (2016) Possible overlapping time frames of acquisition and consolidation phases in object memory processes: a pharmacological approach. Learning & memory (Cold Spring Harbor, NY) 23:29-37.
Allen RM and Young SJ (1978) Phencyclidine-induced psychosis. The American journal of psychiatry 135:1081-1084.
Anand A, Patience AA, Sharma N and Khurana N (2017) The present and future of pharmacotherapy of Alzheimers disease: A comprehensive review. European journal of pharmacology 815:364-375.
Andine P, Widermark N, Axelsson R, Nyberg G, Olofsson U, Martensson E and Sandberg M (1999) Characterization of MK-801-induced behavior as a putative rat model of psychosis. The Journal of pharmacology and experimental therapeutics 290:1393-1408.
Arancio O, Kandel ER and Hawkins RD (1995) Activity-dependent long-term enhancement of transmitter release by presynaptic 3,5 -cyclic GMP in cultured hippocampal neurons. Nature 376:74-80.
Assenza MR, Barbagallo F, Barrios F, Cornacchione M, Campolo F, Vivarelli E, Gianfrilli D, Auletta L, Soricelli A, Isidori AM, Lenzi A, Pellegrini M and Naro F (2018) Critical role of phosphodiesterase 2A in mouse congenital heart defects. Cardiovascular research 114:830-845.
Beavo JA (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiological reviews 75:725-748.
Bernabeu R, Schmitz P, Faillace MP, Izquierdo I and Medina JH (1996) Hippocampal cGMP and cAMP are differentially involved in memory processing of inhibitory avoidance learning. Neuroreport 7:585-588.
Bevins RA and Besheer J (2006) Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study recognition memory. Nat Protoc 1:1306-1311.
Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van Staveren W, de Vente J, Prickaerts J, Blokland A and Koenig G (2004) Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 47:1081-1092.
Bollen E, Akkerman S, Puzzo D, Gulisano W, Palmeri A, DHooge R, Balschun D, Steinbusch HW, Blokland A and Prickaerts J (2015) Object memory enhancement by combining sub-efficacious doses of specific phosphodiesterase inhibitors. Neuropharmacology 95:361-366.
Bollen E, Puzzo D, Rutten K, Privitera L, De Vry J, Vanmierlo T, Kenis G, Palmeri A, DHooge R, Balschun D, Steinbusch HM, Blokland A and Prickaerts J (2014) Improved long-term memory via enhancing cGMP-PKG signaling requires cAMP-PKA signaling. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 39:2497-2505.
Buccafusco JJ, Terry AV, Jr., Webster SJ, Martin D, Hohnadel EJ, Bouchard KA and Warner SE (2008) The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant-conditioning memory tasks for screening drug candidates. Psychopharmacology 199:481-494.
Cayre E, Parachou D, Meot B, Rion B, Drieu Lau Rochelle C, Sheardown M, Ruprah P, Walsh L, Reeves J, Fosbeary R, Barnes M and Patel T (2016) Characterization of PGM039678, a positive allosteric modulator of the muscarinic M4 receptor, in animal models of schizophrenia. Neuroscience 2016.
Cerasti E and Treves A (2010) How informative are spatial CA3 representations established by the dentate gyrus? PLoS computational biology 6:e1000759.
Chalimoniuk M and Strosznajder JB (1998) Aging modulates nitric oxide synthesis and cGMP levels in hippocampus and cerebellum. Effects of amyloid beta peptide. Molecular and chemical neuropathology 35:77-95.
Citri A and Malenka RC (2008) Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 33:18-41.
Clayton DA, Mesches MH, Alvarez E, Bickford PC and Browning MD (2002) A hippocampal NR2B deficit can mimic age-related changes in long-term potentiation and spatial learning in the Fischer 344 rat. The Journal of neuroscience : the official journal of the Society for Neuroscience 22:3628-3637.
Cowburn RF, ONeill C, Ravid R, Alafuzoff I, Winblad B and Fowler CJ (19 92) Adenylyl cyclase activity in postmortem human brain: evidence of altered G protein mediation in Alzheimers disease. Journal of neurochemistry 58:1409-1419.
Coyle JT (1996) The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 3:241-253.
Deardorff WJ, Feen E and Grossberg GT (2015) The Use of Cholinesterase Inhibitors Across All Stages of Alzheimers Disease. Drugs & aging 32:537-547.
Derkach VA, Oh MC, Guire ES and Soderling TR (2007) Regulatory mechanisms of AMPA receptors in synaptic plasticity. Nature reviews Neuroscience 8:101-113.
Domek-Lopacinska K and Strosznajder JB (2008) The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging. Brain Res 1216:68-77.
Domek-Lopacinska K, van de Waarenburg M, Markerink-van Ittersum M, Steinbusch HW and de Vente J (2005) Nitric oxide-induced cGMP synthesis in the cholinergic system during the development and aging of the rat brain. Brain research Developmental brain research 158:72-81.
Esteban JA, Shi SH, Wilson C, Nuriya M, Huganir RL and Malinow R (2003) PKA phosphorylation of AMPA receptor subunits controls synaptic trafficking underlying plasticity. Nature neuroscience 6:136-143.
Fernandez-Fernandez D, Rosenbrock H and Kroker KS (2015) Inhibition of PDE2A, but not PDE9A, modulates presynaptic short-term plasticity measured by paired-pulse facilitation in the CA1 region of the hippocampus. Synapse (New York, NY) 69:484-496.
Foussias G, Agid O, Fervaha G and Remington G (2014) Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 24:693-709.
Francis SH, Blount MA and Corbin JD (2011) Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiological reviews 91:651-690.
Goff DC and Coyle JT (2001) The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. The American journal of psychiatry 158:1367-1377.
Gomez L and Breitenbucher JG (2013) PDE2 inhibition: potential for the treatment of cognitive disorders. Bioorganic & medicinal chemistry letters 23:6522-6527.
Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ and Robbins TW (2000) Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. The Journal of neuroscience : the official journal of the Society for Neuroscience 20:1208-1215.
Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, Langen B, Logue S, Brennan J, Jiang L, Charych E, Egerland U, Liu F, Marquis KL, Malamas M,
Hage T, Comery TA and Brandon NJ (2009) Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. The Journal of pharmacology and experimental therapeutics 331:574-590.
Guidi M, Kumar A and Foster TC (2015) Impaired attention and synaptic senescence of the prefrontal cortex involves redox regulation of NMDA receptors. The Journal of neuroscience : the official journal of the Society for Neuroscience 35:3966-3977.
Gurney ME (2019) Genetic Association of Phosphodiesterases With Human Cognitive Performance. Frontiers in molecular neuroscience 12:22.
Hallak JE, Maia-de-Oliveira JP, Abrao J, Evora PR, Zuardi AW, Crippa JA, Belmonte-de-Abreu P, Baker GB and Dursun SM (2013) Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA psychiatry 70:668-676.
Heckman PR, Blokland A, Ramaekers J and Prickaerts J (2015) PDE and cognitive processing: beyond the memory domain. Neurobiol Learn Mem 119:108-122.
Hosseini-Sharifabad A, Ghahremani MH, Sabzevari O, Naghdi N, Abdollahi M, Beyer C, Bollen E, Prickaerts J, Roghani A and Sharifzadeh M (2012) Effects of protein kinase A and G inhibitors on hippocampal cholinergic markers expressions in rolipram- and sildenafil-induced spatial memory improvement. Pharmacology, biochemistry, and behavior 101:311-319.
Hu F, Ren J, Zhang JE, Zhong W and Luo M (2012) Natriuretic peptides block synaptic transmission by activating phosphodiesterase 2A and reducing presynaptic PKA activity. Proceedings of the National Academy of Sciences of the United States of America 109:17681-17686.
Huntley JD, Hampshire A, Bor D, Owen AM and Howard RJ (2017) The importance of sustained attention in early Alzheimers disease. International journal of geriatric psychiatry 32:860-867.
Ibarra C, Nedvetsky PI, Gerlach M, Riederer P and Schmidt HH (2001) Regional and age-dependent expression of the nitric oxide receptor, soluble guanylyl cyclase, in the human brain. Brain Res 907:54-60.
Javitt DC and Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. The American journal of psychiatry 148:1301-1308.
Jenkins TA, Harte MK, McKibben CE, Elliott JJ and Reynolds GP (2008) Disturbances in social interaction occur along with pathophysiological deficits following sub-chronic phencyclidine administration in the rat. Behavioural brain research 194:230-235.
Jones CA, Watson DJ and Fone KC (2011) Animal models of schizophrenia. British journal of pharmacology 164:1162-1194.
Kapur S and Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Progress in neuro-psychopharmacology & biological psychiatry 27:1081-1090.
Kehler J and Nielsen J (2011) PDE10A inhibitors: novel therapeutic drugs for schizophrenia. Curr Pharm Des 17:137-150.
Kelly MP (2018) Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain. Cellular signalling 42:281-291.
Kleppisch T and Feil R (2009) cGMP signalling in the mammalian brain: role in synaptic plasticity and behaviour. Handbook of experimental pharmacology:549-579.
Kobayashi Y, Sano Y, Vannoni E, Goto H, Suzuki H, Oba A, Kawasaki H, Kanba S, Lipp HP, Murphy NP, Wolfer DP and Itohara S (2013) Genetic dissection of medial habenula-interpeduncular nucleus pathway function in mice. Front Behav Neurosci 7:17.
Lecourtier L and Kelly PH (2007) A conductor hidden in the orchestra? Role of the habenular complex in monoamine transmission and cognition. Neurosci Biobehav Rev 31:658-672.
Lee BH and Kim YK (2008) Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls. Schizophrenia research 104:36-43.
Lee HK, Takamiya K, Han JS, Man H, Kim CH, Rumbaugh G, Yu S, Ding L, He C, Petralia RS, Wenthold RJ, Gallagher M and Huganir RL (2003) Phosphorylation of the AMPA receptor GluR1 subunit is required for synaptic plasticity and retention of spatial memory. Cell 112:631-643.
Leutgeb S, Leutgeb JK, Moser MB and Moser EI (2005) Place cells, spatial maps and the population code for memory. Current opinion in neurobiology 15:738-746.
Lin CH, Lane HY and Tsai GE (2012) Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacology, biochemistry, and behavior 100:665-677.
Lindner MD (1997) Reliability, distribution, and validity of age-related cognitive deficits in the Morris water maze. Neurobiol Learn Mem 68:203-220.
Lithfous S, Dufour A and Despres O (2013) Spatial navigation in normal aging and the prodromal stage of Alzheimers disease: insights from imaging and behavioral studies. Ageing research reviews 12:201-213.
Lowe SL, Bowen DM, Francis PT and Neary D (1990) Ante mortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimers disease. Neuroscience 38:571-577.
Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP and Waldman SA (2000) Guanylyl cyclases and signaling by cyclic GMP. Pharmacological reviews 52:375-414.
Lueptow LM, Zhan CG and ODonnell JM (2016) Cyclic GMP -mediated memory enhancement in the object recognition test by inhibitors of phosphodiesterase-2 in mice. Psychopharmacology 233:447-456.
Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109:366-398.
Marder SR and Fenton W (2004) Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophrenia research 72:5-9.
Martinez M, Frank A, Diez-Tejedor E and Hernanz A (1993) Amino acid concentrations in cerebrospinal fluid and serum in Alzheimers disease and vascular dementia. Journal of neural transmission Parkinsons disease and dementia section 6:1-9.
Maurice DH, Ke H, Ahmad F, Wang Y, Chung J and Manganiello VC (2014) Advances in targeting cyclic nucleotide phosphodiesterases. Nature reviews Drug discovery 13:290-314.
McGauran AM, OMara SM and Commins S (2005) Vestibular influence on water maze retention: transient whole body rotations improve the accuracy of the cue-based retention strategy. Behavioural brain research 158:183-187.
Meador-Woodruff JH and Healy DJ (2000) Glutamate receptor expression in schizophrenic brain. Brain research Brain research reviews 31:288-294.
Messinger JW, Tremeau F, Antonius D, Mendelsohn E, Prudent V, Stanford AD and Malaspina D (2011) Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research. Clin Psychol Rev 31:161-168.
Mesulam M (2004) The cholinergic lesion of Alzheimers disease: pivotal factor or side show? Learning & memory (Cold Spring Harbor, NY) 11:43-49.
Mikami S, Nakamura S, Ashizawa T, Nomura I, Kawasaki M, Sasaki S, Oki H, Kokubo H, Hoffman ID, Zou H, Uchiyama N, Nakashima K, Kamiguchi N, Imada H, Suzuki N, Iwashita H and Taniguchi T (2017) Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy2-oxo-2 ,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders. Journal of medicinal chemistry 60:7677-7702.
Mitsushima D, Ishihara K, Sano A, Kessels HW and Takahashi T (2011) Contextual learning requires synaptic AMPA receptor delivery in the hippocampus. Proceedings of the National Academy of Sciences of the United States of America 108:12503-12508.
Moffat SD (2009) Aging and spatial navigation: what do we know and where do we go? Neuropsychology review 19:478-489.
Moghaddam M and Bures J (1996) Contribution of egocentric spatial memory to place navigation of rats in the Morris water maze. Behavioural brain research 78:121-129.
Mohler EG, Franklin SR, Rueter LE, Fox GB, Decker MW and Browman KE (2010) ABT-594 improves performance in the 5-choice serial reaction time task under conditions of increased difficulty, sub-chronic dosing, and in poorly-performing subjects. Pharmacology, biochemistry, and behavior 95:146-157.
Morris BJ, Cochran SM and Pratt JA (2005) PCP: from pharmacology to modelling schizophrenia. Current opinion in pharmacology 5:101-106.
Morrison RL and Bellack AS (1987) Social functioning of schizophrenic patients: clinical and research issues. Schizophrenia bulletin 13:715-725.
Mortamais M, Ash JA, Harrison J, Kaye J, Kramer J, Randolph C, Pose C, Albala B, Ropacki M, Ritchie CW and Ritchie K (2017) Detecting cognitive changes in preclinical Alzheimers disease: A review of its feasibility. Alzheimers & dementia : the journal of the Alzheimers Association 13:468-492.
Naganawa M, Waterhouse RN, Nabulsi N, Lin SF, Labaree D, Ropchan J, Tarabar S, DeMartinis N, Ogden A, Banerjee A, Huang Y and Carson RE (2016) First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 57:1388-1395.
Nakano Y, Yoshimura R, Nakano H, Ikenouchi-Sugita A, Hori H, Umene-Nakano W, Ueda N and Nakamura J (2010) Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study. Human psychopharmacology 25:139-144.
Nakashima M, Imada H, Shiraishi E, Ito Y, Suzuki N, Miyamoto M, Taniguchi T and Iwashita H (2018) Phosphodiesterase 2A Inhibitor TAK-915 Ameliorates Cognitive Impairments and Social Withdrawal in N-Methyl-d-Aspartate Receptor Antagonist-Induced Rat Models of Schizophrenia. The Journal of pharmacology and experimental therapeutics 365:179-188.
Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, Snigdha S, Rajagopal L and Harte MK (2010) Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 128:419-432.
Neill JC, Harte MK, Haddad PM, Lydall ES and Dwyer DM (2014) Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 24:822-835.
Neitz A, Mergia E, Eysel UT, Koesling D and Mittmann T (2011) Presynaptic nitric oxide/cGMP facilitates glutamate release via hyperpolarization-activated cyclic nucleotide-gated channels in the hippocampus. Eur J Neurosci 33:1611-1621.
Nishiyama K, Suzuki H, Harasawa T, Suzuki N, Kurimoto E, Kawai T, Maruyama M, Komatsu H, Sakuma K, Shimizu Y and Shimojo M (2017) FTBMT, a Novel and Selective GPR52 Agonist, Demonstrates Antipsychotic-Like and Procognitive Effects in Rodents, Revealing a Potential Therapeutic Agent for Schizophrenia. The Journal of pharmacology and experimental therapeutics 363:253-264.
OMara SM, Sanchez -Vives MV, Brotons-Mas JR and OHare E (2009) Roles for the subiculum in spatial information processing, memory, motivation and the temporal control of behaviour. Progress in neuro-psychopharmacology & biological psychiatry 33:782-790.
Olney JW and Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007.
Paine TA, Neve RL and Carlezon WA, Jr. (2009) Attention deficits and hyperactivity following inhibition of cAMP-dependent protein kinase within the medial prefrontal cortex of rats. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 34:2143-2155.
Parasuraman R and Nestor PG (1991) Attention and driving skills in aging and Alzheimers disease. Human factors 33:539-557.
Patel NS, Klett J, Pilarzyk K, Lee DI, Kass D, Menniti FS and Kelly MP (2018) Identification of new PDE9A isoforms and how their expression and subcellular compartmentalization in the brain change across the life span. Neurobiology of aging 65:217-234.
Perry RJ, Watson P and Hodges JR (2000) The nature and staging of attentiondysfunction in early (minimal and mild) Alzheimers disease: relationship to episodic and semantic memory impairment. Neuropsychologia 38:252-271.
Piskulic D, Olver JS, Norman TR and Maruff P (2007) Behavioural studies of spatial working memory dysfunction in schizophrenia: a quantitative literature review. Psychiatry Res 150:111-121.
Pogue-Geile MF and Harrow M (1985) Negative symptoms in schizophrenia: their longitudinal course and prognostic importance. Schizophrenia bulletin 11:427-439.
Portero-Tresserra M, Marti-Nicolovius M, Tarres-Gatius M, Candalija A, Guillazo-Blanch G and Vale-Martinez A (2018) Intra-hippocampal D-cycloserine rescues decreased social memory, spatial learning reversal, and synaptophysin levels in aged rats. Psychopharmacology 235:1463-1477.
Puig O, Penades R, Gasto C, Catalan R, Torres A and Salamero M (2008) Verbal memory, negative symptomatology and prediction of psychosocial functioning in schizophrenia. Psychiatry Res 158:11-17.
Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L and Oremus M (2008) Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Annals of internal medicine 148:379-397.
Redrobe JP, Jorgensen M, Christoffersen CT, Montezinho LP, Bastlund JF, Carnerup M, Bundgaard C, Lerdrup L and Plath N (2014) In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia. Psychopharmacology 231:3151-3167.
Reid W, Broe G, Creasey H, Grayson D, McCusker E, Bennett H, Longley W and Sulway MR (1996) Age at onset and pattern of neuropsychological impairment in mild early-stage Alzheimer disease. A study of a community-based population. Archives of neurology 53:1056-1061.
Reneerkens OA, Rutten K, Bollen E, Hage T, Blokland A, Steinbusch HW and Prickaerts J (2013) Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801. Behavioural brain research 236:16-22.
Reyes-Irisarri E, Markerink-Van Ittersum M, Mengod G and de Vente J (2007) Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimers disease human br ains. Eur J Neurosci 25:3332-3338.
Russwurm C, Zoidl G, Koesling D and Russwurm M (2009) Dual acylation of PDE2A splice variant 3: targeting to synaptic membranes. The Journal of biological chemistry 284:25782-25790.
Rutten K, Prickaerts J, Hendrix M, van der Staay FJ, Sik A and Blokland A (2007) Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. European journal of pharmacology 558:107-112.
Schaefer J, Giangrande E, Weinberger DR and Dickinson D (2013) The global cognitive impairment in schizophrenia: consistent over decades and around the world. Schizophrenia research 150:42-50.
Schoffelmeer AN, Wardeh G and Mulder AH (1985) Cyclic AMP facilitates the electrically evoked release of radiolabelled noradrenaline, dopamine and 5-hydroxytryptamine from rat brain slices. Naunyn-Schmiedebergs archives of pharmacology 330:74-76.
Serulle Y, Arancio O and Ziff EB (2008) A role for cGMP-dependent protein kinase II in AMPA receptor trafficking and synaptic plasticity. Channels (Austin, Tex) 2:230-232.
Serulle Y, Zhang S, Ninan I, Puzzo D, McCarthy M, Khatri L, Arancio O and Ziff EB (2007) A GluR1-cGKII interaction regulates AMPA receptor trafficking. Neuron 56:670-688.
Shamsi S, Lau A, Lencz T, Burdick KE, DeRosse P, Brenner R, Lindenmayer JP and Malhotra AK (2011) Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophrenia research 126:257-264.
Shepherd JD and Huganir RL (2007) The cell biology of synaptic plasticity: AMPA receptor trafficking. Annual review of cell and developmental biology 23:613-643.
Shiraishi E, Suzuki K, Harada A, Suzuki N and Kimura H (2016) The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models. The Journal of pharmacology and experimental therapeutics 356:587-595.
Sierksma AS, Rutten K, Sydlik S, Rostamian S, Steinbusch HW, van den Hove DL and Prickaerts J (2013) Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimers disease. Neuropharmacology 64:124-136.
Stephenson DT, Coskran TM, Kelly MP, Kleiman RJ, Morton D, ONeill SM, Schmidt CJ, Weinberg RJ and Menniti FS (2012) The distribution of phosphodiesterase 2A in the rat brain. Neuroscience 226:145-155.
Stephenson DT, Coskran TM, Wilhelms MB, Adamowicz WO, ODonnell MM, Muravnick KB, Menniti FS, Kleiman RJ and Morton D (2009) Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 57:933-949.
Suvarna NU and ODonnell JM (2002) Hydrolysis of N -methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus. The Journal of pharmacology and experimental therapeutics 302:249-256.
Suzuki K, Harada A, Shiraishi E and Kimura H (2015) In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents. The Journal of pharmacology and experimental therapeutics 352:471-479.
Suzuki K, Harada A, Suzuki H, Miyamoto M and Kimura H (2016) TAK-063, a PDE10A Inhibitor with Balanced Activation of Direct and Indirect Pathways, Provides Potent Antipsychotic-Like Effects in Multiple Paradigms. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 41:2252-2262.
Takahashi H, Fukumoto H, Maeda R, Terauchi J, Kato K and Miyamoto M (2010) Ameliorative effects of a non-competitive BACE1 inhibitor TAK-070 on Abeta peptide levels and impaired learning behavior in aged rats. Brain Res 1361:146-156.
Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, Jiang T, Zhu XC and Tan L (2014) Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimers disease: a systematic review and meta-analysis. Journal of Alzheimers disease : JAD 41:615-631.
Tariot PN, Patel SV, Cox C and Henderson RE (1996) Age-related decline in central cholinergic function demonstrated with scopolamine. Psychopharmacology 125:50-56.
Taylor JR, Birnbaum S, Ubriani R and Arnsten AF (1999) Activation of cAMP-dependent protein kinase A in prefrontal cortex impairs working memory performance. The Journal of neuroscience : the official journal of the Society for Neuroscience 19:RC23.
Thompson S, Lanctot KL and Herrmann N (2004) The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimers disease. Expert opinion on drug safety 3:425-440.
Torgalsboen AK, Mohn C, Czajkowski N and Rund BR (2015) Relationship between neurocognition and functional recovery in first-episode schizophrenia: Results from the second year of the Oslo multi-follow-up study. Psychiatry Res.
Ugarte A, Gil-Bea F, Garcia-Barroso C, Cedazo-Minguez A, Ramirez MJ, Franco R, Garcia-Osta A, Oyarzabal J and Cuadrado-Tejedor M (2015) Decreased levels of guanosine 3, 5 -monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimers disease. Neuropathology and applied neurobiology 41:471-482.
Vallebuona F and Raiteri M (1995) Age-related changes in the NMDA receptor/nitric oxide/cGMP pathway in the hippocampus and cerebellum of freely moving rats subjected to transcerebral microdialysis. Eur J Neurosci 7:694-701.
van der Staay FJ, Rutten K, Erb C and Blokland A (2011) Effects of the cognition impairer MK-801 on learning and memory in mice and rats. Behavioural brain research 220:215-229.
Verhoest PR, Chapin DS, Corman M, Fonseca K, Harms JF, Hou X, Marr ES, Menniti FS, Nelson F, OConnor R, Pandit J, Proulx -Lafrance C, Schmidt AW, Schmidt CJ, Suiciak JA and Liras S (2009) Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. Journal of medicinal chemistry 52:5188-5196.
Wang JQ, Arora A, Yang L, Parelkar NK, Zhang G, Liu X, Choe ES and Mao L (2005) Phosphorylation of AMPA receptors: mechanisms and synaptic plasticity. Mol Neurobiol 32:237-249.
Wilson CA and Koenig JI (2014) Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 24:759-773.
Witter MP and Moser EI (2006) Spatial representation and the architecture of the entorhinal cortex. Trends in neurosciences 29:671-678.
論文の公開元へ
